# planB (NCT01049425)

> Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01049425
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Women's Cancer Study Group GmbH
- Conditions: Primary Breast Cancer; Her2 Non-overexpressing
- Interventions: Epirubicin; Cyclophosphamide; Docetaxel; Cyclophosphamide; Docetaxel
- Enrollment: 3198
- Primary outcome: disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatment

## Commentary we found

- X threads: 11
- YouTube: 9
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=planb-nct01049425

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01049425", "email": "<work email>"}; the inbox owner confirms by the emailed link.